Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC? Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC?

A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news